Home › Funds › BRAIDWELL LP › NRIX
BRAIDWELL LP position in NRIX
NURIX THERAPEUTICS INC · Health Care
BRAIDWELL LP reported holding 1,286,769 shares of NRIX (NURIX THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$31.2M, representing 1.23% of its reported portfolio and ranking #32 among its reported holdings. BRAIDWELL LP has disclosed NRIX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's NRIX position evolved
BRAIDWELL LP first disclosed a stake in NRIX in Q4 2025 at 2,183,864 shares (US$41.4M). Across 3 filings, BRAIDWELL LP increased the stake 0 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 1,286,769 shares valued at US$31.2M — a reduction of -463,997 shares quarter over quarter.. Notable position changes include a 27% trim in Q2 2026 (shares fell 2% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 2.18M | $41.43M | New |
| Q1 2026 | 1.75M | $27.14M | Reduce |
| Q2 2026 | 1.29M | $31.22M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NRIX and 13F data
NRIX (NURIX THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in NRIX — the largest reported positions include Vestal Point Capital, LP (US$195.3M), Deep Track Capital, LP (US$187.7M), Rubric Capital Management LP (US$175.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NRIX
- Vestal Point Capital, LP 8.05M sh · $195.29M · Q2 2026
- Deep Track Capital, LP 7.74M sh · $187.69M · Q2 2026
- Rubric Capital Management LP 7.23M sh · $175.35M · Q2 2026
- BAKER BROS. ADVISORS LP 4.66M sh · $113.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.32M sh · $104.81M · Q2 2026
- Redmile Group, LLC 4.07M sh · $98.83M · Q2 2026
- GENERAL ATLANTIC, L.P. 3.03M sh · $73.56M · Q2 2026
- Trails Edge Capital Partners, LP 1.57M sh · $38.17M · Q2 2026
- Soleus Capital Management, L.P. 1.47M sh · $35.54M · Q2 2026
- Kynam Capital Management, LP 1.19M sh · $28.98M · Q2 2026
- Affinity Asset Advisors, LLC 967.62K sh · $23.47M · Q2 2026
- Rhenman & Partners Asset Management AB 684.25K sh · $16.60M · Q2 2026
More on BRAIDWELL LP
FAQ
How long has BRAIDWELL LP held NRIX?
BRAIDWELL LP has disclosed NRIX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is BRAIDWELL LP's current position in NRIX?
As of Q2 2026, BRAIDWELL LP holds 1.29M shares of NRIX (NURIX THERAPEUTICS INC), valued at $31.22M, representing 1.23% of its reported portfolio and ranking #32.
Has BRAIDWELL LP been buying or selling NRIX?
In the latest 13F filing (Q2 2026), BRAIDWELL LP reduced its position in NRIX.
Which other funds hold NRIX?
Other major institutional holders of NRIX include Vestal Point Capital, LP, Deep Track Capital, LP, Rubric Capital Management LP, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.